2012 Outlook Maintained As Key Drug Policy Reforms Pass Parliament Before Government Falls

BMI View: Our weak 2012 outlook for Slovakia's pharmaceutical market has been maintained with the passage of key drug policy reforms in September, prior to the fall of Iveta Radicová's government in early October. The government's most significant and damaging measure is the introduction of a stricter reference pricing model. From January 2012, drug prices will be set to the average of the two lowest prices in the EU, replacing the current system in which medicines cannot exceed the average price of the six lowest prices for drugs in other EU markets.

To read the full article, please choose one of the following options: